Investigational New Drug application for KHN921 received 'study may proceed” from the US FDA. KHN921 is a potential 'first-in-class' cardiovascular AAV gene therapy being developed for the treatment o ...
Bank of America Global Healthcare Conference 2026 May 13, 2026 2:20 PM EDTCompany ParticipantsDouglas Love - CEO, President ...
Investigational New Drug application for KHN921 received "study may proceed" from the US FDA. KHN921 is a potential "first-in-class" cardiovascular AAV gene therapy being developed for the treatment o ...
May 13, 2026, at 4:30 p.m. ET President & Chief Executive Officer — Dr. Yves LeMaitre Head of Investor Relations — Ryan Coleman Need a quote from a Motley Fool analyst? Email pr@fool.com Revenue -- ...
AMD’s desktop app for running models locally is still in the early stages, with few configuration options and no support for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results